Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allos Therapeutics, Inc.
Allos Therapeutics Reports 2008 Results
March 17th, 2009
Allos Therapeutics, Inc. (Nasdaq: ALTH) reported results for its fiscal year ended December 31, 2008 and outlined its key objectives for 2009. For the year ended December 31, 2008, the Company reported a net loss of $51.7 million, or $0.69 per share, compared to a net loss of $39.4 million, or $0.60 per share, for 2007. Net cash used in operating activities during 2008 was $42.9 million. Cash, cash equivalents and investments in marketable securities as of December 31, 2008 totaled $84.0 million. “During 2008, we made significant advancements in our pralatrexate product development and commercialization plan,” said Paul L. Berns, President and Chief Executive Officer....
Source: Cancer Weekly (2009-03-17)
|
